While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

(Reuters) -Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Medical professionals are raising concerns about patients who discontinue popular weight loss medications experiencing significant weight regain. The National Institute for Health and Care Excellence ...